[go: up one dir, main page]

WO2001078783A3 - Compositions comprising natural agents for treatment of cancer - Google Patents

Compositions comprising natural agents for treatment of cancer Download PDF

Info

Publication number
WO2001078783A3
WO2001078783A3 PCT/US2001/012096 US0112096W WO0178783A3 WO 2001078783 A3 WO2001078783 A3 WO 2001078783A3 US 0112096 W US0112096 W US 0112096W WO 0178783 A3 WO0178783 A3 WO 0178783A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
cancer
natural agents
treatment
natural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/012096
Other languages
French (fr)
Other versions
WO2001078783A2 (en
Inventor
John Boik
Robert A Newman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hauser Inc
University of Texas System
University of Texas at Austin
Original Assignee
Hauser Inc
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hauser Inc, University of Texas System, University of Texas at Austin filed Critical Hauser Inc
Priority to AU5160201A priority Critical patent/AU5160201A/en
Publication of WO2001078783A2 publication Critical patent/WO2001078783A2/en
Publication of WO2001078783A3 publication Critical patent/WO2001078783A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions are provided comprising five or more natural agents combined into one formulation, each natural agent possessing known anticancer activity, wherein the natural agents in the composition interact synergistically to enhance their anticancer activities. The compositions of this invention demonstrate in vitro inhibition of cancer cell proliferation and provide potential candidates for cancer therapies.
PCT/US2001/012096 2000-04-17 2001-04-13 Compositions comprising natural agents for treatment of cancer Ceased WO2001078783A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU5160201A AU5160201A (en) 2000-04-17 2001-04-13 Compositions comprising natural agents for treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55043600A 2000-04-17 2000-04-17
US09/550,436 2000-04-17

Publications (2)

Publication Number Publication Date
WO2001078783A2 WO2001078783A2 (en) 2001-10-25
WO2001078783A3 true WO2001078783A3 (en) 2002-07-04

Family

ID=24197183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012096 Ceased WO2001078783A2 (en) 2000-04-17 2001-04-13 Compositions comprising natural agents for treatment of cancer

Country Status (2)

Country Link
AU (1) AU5160201A (en)
WO (1) WO2001078783A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663679B2 (en) 2004-04-29 2014-03-04 Abbott Laboratories Compositions for improving breast health in women

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001256855A1 (en) * 2000-05-08 2001-11-20 N.V. Nutricia Preparation for the prevention and treatment of ocular disorders
EP1487434B1 (en) * 2002-03-06 2007-05-09 The Medical Research and Education Trust Botanical extract compositions with anti-cancer activity comprising isoliquiritigenin
WO2004012662A2 (en) * 2002-08-01 2004-02-12 Aesgen, Inc. Improved treatment of cancer with glutamine
ITMI20022352A1 (en) * 2002-11-06 2004-05-07 Univ Catania ANTI-CANCER PREPARATIONS CONTAINING RESVERATROL AND PROPOLIS.
ITFI20050031A1 (en) * 2005-02-21 2006-08-22 Stefan Coccoloni A PHARMACEUTICAL COMPOSITION TO PREVENT THE AGING AND THE RISING OF VASCULAR, NEOPLASTIC, CUTANEOUS AND PILIFEROUS DISEASES
US20080317885A1 (en) * 2005-07-15 2008-12-25 Baker Donald J Compositions and Methods for Treating and Preventing Inflammatory and/or Degenerative Processes in Humans and Other Animals
WO2007042272A2 (en) * 2005-10-14 2007-04-19 Dsm Ip Assets B.V. Use of a nutraceutical composition comprising resveratrol for the treatment of age-related diseases
GB0800134D0 (en) * 2008-01-04 2008-02-13 Univ Nottingham Ganoderma lucidum extracts for use in the treatment of cell neoplasia, cell proliferation and angiogenesis
US20110165291A1 (en) * 2008-11-12 2011-07-07 Andrew Loblaw Nutritional supplement
CN102309474B (en) * 2010-07-02 2013-08-21 复旦大学 Application of S-propargyl-cysteine in preparation of medicament for treating digestive system tumors
EP2420289A1 (en) * 2010-08-18 2012-02-22 Grindeks, a joint stock company Composition of caffeic acid phenethyl ester (CAPE) and one of catechin, kaempherol and myricetin for potentiating antitumour effect and for treating tumours
EP2629766B1 (en) * 2010-10-18 2017-02-22 Chemigen Combination therapy
CN103127093B (en) * 2011-12-02 2016-03-02 鲁南制药集团股份有限公司 The purposes of arctigenin in preparation treatment or prevention cerebral glioma medicine
BR112015024537B1 (en) 2013-04-12 2022-09-06 Ned Biosystems, Inc USE OF (I) CYCLOPHOSPHAMIDE, (II) METFORMIN, (III) CURCUMIN, (IV) MELATONIN, (V) NALTREXONE, (VI) ALPHA LIPOIC ACID AND (VII) GENISTEIN AND COMBINATION IN THE TREATMENT OF CANCER
ITMI20131495A1 (en) 2013-09-10 2015-03-11 Ce R C Ar Di Paolo Maestri USEFUL COMPOSITIONS FOR CHEMOTHERAPY-RESISTANT CANCER TREATMENT
CN104151392A (en) * 2014-05-19 2014-11-19 浙江大学 Moebioside A as well as preparation and application thereof
US10537606B2 (en) * 2014-06-20 2020-01-21 Omni Cure Ltd. Phyto-active based anti-cancer formulation
CN106535939B (en) 2014-07-17 2020-08-18 益生菌股份公司 Compositions comprising melatonin and flavonoids for the treatment of chemotherapy-resistant tumors
WO2016139625A1 (en) 2015-03-05 2016-09-09 Probiotical S.P.A. Compositions for use in the treatment of tumors resistant to chemotherapy
US20180139997A1 (en) * 2015-06-15 2018-05-24 Gexnano S.R.L. Food supplement for use in a process of metabolic rebalancing
CN106389180B (en) * 2015-07-29 2018-12-11 云南康恩贝植物研究院有限公司 A kind of ginkgo procyanidine-polysaccharide mixed extract and its preparation method and application
CN105147655A (en) * 2015-09-07 2015-12-16 深圳市泰华细胞工程有限公司 New purpose of SAMC (S-allylmercaptocysteine)
WO2023014818A2 (en) * 2021-08-03 2023-02-09 Pebble Global Holdings Non-psychoactive multi-cannabinoid and terpene-based therapeutic compositions and methods of their administration
CN116196305B (en) * 2023-03-15 2024-07-23 山东农业大学 A composition and its application in preventing and treating lung damage caused by cadmium

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2100669A1 (en) * 1970-05-20 1972-03-24 American General Entrepr Ant-ageing lung-protecting compns
WO2000070949A1 (en) * 1999-05-20 2000-11-30 Heng Madalene C Y Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2100669A1 (en) * 1970-05-20 1972-03-24 American General Entrepr Ant-ageing lung-protecting compns
WO2000070949A1 (en) * 1999-05-20 2000-11-30 Heng Madalene C Y Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M.G.L. HERTOG E.A.: "Intake and potentially anticarcinogenic flavonoids and their determinants in adults in the netherlands", NUTRITION AND CANCER, vol. 20, no. 1, 1993, pages 21 - 29, XP001073425 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663679B2 (en) 2004-04-29 2014-03-04 Abbott Laboratories Compositions for improving breast health in women

Also Published As

Publication number Publication date
AU5160201A (en) 2001-10-30
WO2001078783A2 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
WO2001078783A3 (en) Compositions comprising natural agents for treatment of cancer
WO2001012199A3 (en) Methoxyamine potentiation of temozolomide anti-cancer activity
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2006055561A3 (en) Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
IL140710A0 (en) Pulmonary delivery of active agents
WO2007011962A3 (en) Treatment of cancer
MY143795A (en) Tetrahydropyridoindole derivatives
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
DE69533551D1 (en) CAMPTOTHECIN DRUG COMBINATIONS WITH REDUCED SIDE EFFECTS
HUP0300798A3 (en) Substituted-triazolopyrimidines and their use as anticancer agents and pharmaceutical compositions containing them
TW200519110A (en) Substituted tetrahydro-1H-pyrazolo [3, 4-c] pyridines, compositions comprising them, and use
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
WO2003070283A3 (en) Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
WO2001023405A3 (en) Therapeutic treatment of androgen receptor driven conditions
WO2002019981A3 (en) Cosmetic and pharmaceutical composition comprising chelating/sequestering agents and their cosmetic and dermatological use
BR0206046A (en) Uses of a combination of protopanaxadiol sapogenin or protopanaxatriol sapogenin, and, pharmaceutical composition
IL150953A0 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2007062413A3 (en) Use of parp-1 inhibitors
WO2002070464A3 (en) Hydrazones and their therapeutic use
WO2002030941A3 (en) Topoisomerase inhibitors
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
WO2003012051A8 (en) Inhibitor of dna methylation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP